

Na-Qiong Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3218535/publications.pdf>

Version: 2024-02-01

122
papers

2,190
citations

304743

22
h-index

345221

36
g-index

124
all docs

124
docs citations

124
times ranked

2396
citing authors

#	ARTICLE	IF	CITATIONS
1	NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study. <i>Lipids in Health and Disease</i> , 2022, 21, 3.	3.0	5
2	Lipoprotein (a)-mediated vascular calcification: population-based and in vitro studies. <i>Metabolism: Clinical and Experimental</i> , 2022, 127, 154960.	3.4	13
3	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity C-Reactive Protein in Patients With Previous Myocardial Infarction. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 797297.	2.4	1
4	Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 763516.	2.4	24
5	Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease. <i>Frontiers in Endocrinology</i> , 2022, 13, 860698.	3.5	0
6	SORBS2 as a molecular target for atherosclerosis in patients with familial hypercholesterolemia. <i>Journal of Translational Medicine</i> , 2022, 20, 233.	4.4	2
7	Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome. <i>Journal of Translational Medicine</i> , 2022, 20, .	4.4	10
8	Lipoprotein(a) and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: A Prospective Cohort Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1161-1168.	3.4	12
9	Atherogenic dyslipidaemia and cardiovascular events in patients with diabetes or pre-diabetes and stable coronary artery disease: a prospective, cohort study. <i>BMJ Open</i> , 2021, 11, e037340.	1.9	2
10	Impact of liver fibrosis score on prognosis in patients with previous myocardial infarction: A prospective cohort study. <i>Liver International</i> , 2021, 41, 1294-1304.	3.9	12
11	Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease. <i>Hepatology International</i> , 2021, 15, 413-423.	4.2	27
12	Impact of diabetes on coronary severity and cardiovascular outcomes in patients with heterozygous familial hypercholesterolaemia. <i>European Journal of Preventive Cardiology</i> , 2021, , .	1.8	11
13	The difference between fasting and non-fasting lipid measurements is not related to statin treatment. <i>Annals of Translational Medicine</i> , 2021, 9, 386-386.	1.7	8
14	Prognostic value of NT-proBNP in patients with chronic coronary syndrome and normal left ventricular systolic function according to glucose status: a prospective cohort study. <i>Cardiovascular Diabetology</i> , 2021, 20, 84.	6.8	17
15	Visit-to-visit variability of lipid and cardiovascular events in patients with familial hypercholesterolemia. <i>Annals of Translational Medicine</i> , 2021, 9, 556-556.	1.7	0
16	Lipoprotein (a), hypertension, and cardiovascular outcomes: a prospective study of patients with stable coronary artery disease. <i>Hypertension Research</i> , 2021, 44, 1158-1167.	2.7	10
17	Association of triglyceride-rich lipoprotein-cholesterol with recurrent cardiovascular events in statin-treated patients according to different inflammatory status. <i>Atherosclerosis</i> , 2021, 330, 29-35.	0.8	9
18	Association of diabetes mellitus with clinical outcomes in patients with different coronary artery stenosis. <i>Cardiovascular Diabetology</i> , 2021, 20, 214.	6.8	8

#	ARTICLE	IF	CITATIONS
19	Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case-control study. <i>Hepatology International</i> , 2021, 15, 1337-1346.	4.2	15
20	Improvement of evaluation in Chinese patients with atherosclerotic cardiovascular disease using the very-high-risk refinement: a population-based study. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 17, 100286.	2.9	6
21	Association of small dense LDL-cholesterol with disease severity, hypertension status and clinical outcome in patients with coronary artery disease. <i>Journal of Hypertension</i> , 2021, 39, 511-518.	0.5	9
22	Association of circulating proprotein convertase subtilisin/kexin type 9 concentration, prothrombin time and cardiovascular outcomes: a prospective cohort study. <i>Thrombosis Journal</i> , 2021, 19, 90.	2.1	5
23	Relations of physical signs to genotype, lipid and inflammatory markers, coronary stenosis or calcification, and outcomes in patients with heterozygous familial hypercholesterolemia. <i>Journal of Translational Medicine</i> , 2021, 19, 498.	4.4	5
24	Lipoprotein(a) Is Associated with the Presence and Severity of New-Onset Coronary Artery Disease in Postmenopausal Women. <i>Journal of Women's Health</i> , 2020, 29, 503-510.	3.3	7
25	Prognostic utility of lipoprotein(a) combined with fibrinogen in patients with stable coronary artery disease: a prospective, large cohort study. <i>Journal of Translational Medicine</i> , 2020, 18, 373.	4.4	9
26	Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study. <i>Cardiovascular Diabetology</i> , 2020, 19, 167.	6.8	25
27	Long-term prognostic utility of low-density lipoprotein (LDL) triglyceride in real-world patients with coronary artery disease and diabetes or prediabetes. <i>Cardiovascular Diabetology</i> , 2020, 19, 152.	6.8	9
28	Association of plasma free fatty acids levels with the presence and severity of coronary and carotid atherosclerotic plaque in patients with type 2 diabetes mellitus. <i>BMC Endocrine Disorders</i> , 2020, 20, 156.	2.2	18
29	Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 837-851.	3.3	8
30	The Prevalence of Familial Hypercholesterolemia (FH) in Chinese Patients With Acute Myocardial Infarction (AMI): Data From Chinese Acute Myocardial Infarction (CAMI) Registry. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 113.	2.4	4
31	Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease. <i>Journal of Lipid Research</i> , 2020, 61, 1254-1262.	4.2	25
32	Differential leukocyte counts and cardiovascular mortality in very old patients with acute myocardial infarction: a Chinese cohort study. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 465.	1.7	10
33	Heart-type fatty acid binding protein predicts cardiovascular events in patients with stable coronary artery disease: a prospective cohort study. <i>Annals of Translational Medicine</i> , 2020, 8, 1349-1349.	1.7	8
34	Association of lipoprotein(a) levels with recurrent events in patients with coronary artery disease. <i>Heart</i> , 2020, 106, 1228-1235.	2.9	28
35	Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1 α and activating FoxO3a. <i>Journal of Translational Medicine</i> , 2020, 18, 195.	4.4	22
36	Fibrinogen is associated with glucose metabolism and cardiovascular outcomes in patients with coronary artery disease. <i>Cardiovascular Diabetology</i> , 2020, 19, 36.	6.8	24

#	ARTICLE	IF	CITATIONS
37	The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes. <i>Cardiovascular Diabetology</i> , 2020, 19, 104.	6.8	42
38	Lipoprotein (a) predicts recurrent worse outcomes in type 2 diabetes mellitus patients with prior cardiovascular events: a prospective, observational cohort study. <i>Cardiovascular Diabetology</i> , 2020, 19, 111.	6.8	24
39	Prognostic utility of heart-type fatty acid-binding protein in patients with stable coronary artery disease and impaired glucose metabolism: a cohort study. <i>Cardiovascular Diabetology</i> , 2020, 19, 15.	6.8	10
40	Association of small dense low-density lipoprotein with cardiovascular outcome in patients with coronary artery disease and diabetes: a prospective, observational cohort study. <i>Cardiovascular Diabetology</i> , 2020, 19, 45.	6.8	44
41	Association of serum lipoprotein(a) level with the severity and prognosis of calcific aortic valve stenosis: a Chinese cohort study. <i>Journal of Geriatric Cardiology</i> , 2020, 17, 133-140.	0.2	4
42	Plasma Lipoprotein(a) Concentration Is Associated With the Coronary Severity but Not With Events in Stable Coronary Artery Disease Patients: A Chinese Cohort Study. <i>Heart Lung and Circulation</i> , 2019, 28, 1009-1017.	0.4	13
43	A modified algorithm with lipoprotein(a) added for diagnosis of familial hypercholesterolemia. <i>Clinical Cardiology</i> , 2019, 42, 988-994.	1.8	7
44	Relation of oxidized-low-density lipoprotein and high-density lipoprotein subfractions in non-treated patients with coronary artery disease. <i>Prostaglandins and Other Lipid Mediators</i> , 2019, 144, 106345.	1.9	9
45	Impact of free fatty acids on prognosis in coronary artery disease patients under different glucose metabolism status. <i>Cardiovascular Diabetology</i> , 2019, 18, 134.	6.8	20
46	Baseline and on-statin treatment lipoprotein(a) levels for predicting cardiovascular events in patients with familial hypercholesterolemia. <i>Atherosclerosis</i> , 2019, 291, 27-33.	0.8	13
47	Differences in phenotype, genotype and cardiovascular events between patients with probable and definite heterozygous familial hypercholesterolemia. <i>Personalized Medicine</i> , 2019, 16, 467-478.	1.5	1
48	Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy. <i>Journal of Translational Medicine</i> , 2019, 17, 367.	4.4	20
49	Free fatty acids as a marker for predicting periprocedural myocardial injury after coronary intervention. <i>Postgraduate Medical Journal</i> , 2019, 95, 18-22.	1.8	6
50	High-sensitivity C-reactive protein and hypertension: combined effects on coronary severity and cardiovascular outcomes. <i>Hypertension Research</i> , 2019, 42, 1783-1793.	2.7	14
51	A Novel Modified System of Simplified Chinese Criteria for Familial Hypercholesterolemia (SCCFH). <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 547-553.	3.8	9
52	Lipoprotein(a) and Cardiovascular Outcomes in Patients With Coronary Artery Disease and Prediabetes or Diabetes. <i>Diabetes Care</i> , 2019, 42, 1312-1318.	8.6	82
53	Rapid Regression of Multiple-Site Xanthomas in an Adult With Homozygous Familial Hypercholesterolemia by Triple Lipid-Lowering Drugs. <i>American Journal of Therapeutics</i> , 2019, 26, e775-e777.	0.9	2
54	Impact of Non-Alcoholic Fatty Liver Disease on Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease: A Matched Case-€“Control Study. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00011.	2.5	18

#	ARTICLE	IF	CITATIONS
55	Poor Response to Alirocumab in a Patient With Homozygous Familial Hypercholesterolemia. <i>American Journal of Therapeutics</i> , 2019, 26, e743-e745.	0.9	2
56	Impacts of Prediabetes Mellitus Alone or Plus Hypertension on the Coronary Severity and Cardiovascular Outcomes. <i>Hypertension</i> , 2018, 71, 1039-1046.	2.7	68
57	Lipoprotein(a) level associates with coronary artery disease rather than carotid lesions in patients with familial hypercholesterolemia. <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, e22442.	2.1	15
58	Impact of glucose and lipid markers on the correlation of calculated and enzymatic measured low-density lipoprotein cholesterol in diabetic patients with coronary artery disease. <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, e22399.	2.1	3
59	Novel findings in relation to multiple anti-atherosclerotic effects of XueZhiKang in humans. <i>Chronic Diseases and Translational Medicine</i> , 2018, 4, 117-126.	1.2	4
60	Predictive value of big endothelin-1 on outcomes in patients with myocardial infarction younger than 35 years old. <i>Personalized Medicine</i> , 2018, 15, 25-33.	1.5	4
61	Association between plasma proprotein convertase subtilisin/kexin type 9 concentration and coronary artery calcification. <i>Annals of Clinical Biochemistry</i> , 2018, 55, 158-164.	1.6	19
62	Association between lipoprotein (a) and proprotein convertase subtilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study. <i>Metabolism: Clinical and Experimental</i> , 2018, 79, 33-41.	3.4	18
63	Triglyceride glucose index for predicting cardiovascular outcomes in patients with coronary artery disease. <i>Journal of Thoracic Disease</i> , 2018, 10, 6137-6146.	1.4	122
64	Recurrent Cardiac Tamponade from Right Atrial Angiosarcoma. <i>Chinese Medical Journal</i> , 2018, 131, 1379-1380.	2.3	2
65	Genetic basis of index patients with familial hypercholesterolemia in Chinese population: mutation spectrum and genotype-phenotype correlation. <i>Lipids in Health and Disease</i> , 2018, 17, 252.	3.0	19
66	Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers. <i>Lipids in Health and Disease</i> , 2018, 17, 265.	3.0	18
67	Intensive genetic analysis for Chinese patients with very high triglyceride levels: Relations of mutations to triglyceride levels and acute pancreatitis. <i>EBioMedicine</i> , 2018, 38, 171-177.	6.1	22
68	Application of expanded genetic analysis in the diagnosis of familial hypercholesterolemia in patients with very early-onset coronary artery disease. <i>Journal of Translational Medicine</i> , 2018, 16, 345.	4.4	27
69	Oxidized-LDL is a useful marker for predicting the very early coronary artery disease and cardiovascular outcomes. <i>Personalized Medicine</i> , 2018, 15, 521-529.	1.5	9
70	Triglyceride glucose and haemoglobin glycation index for predicting outcomes in diabetes patients with new-onset, stable coronary artery disease: a nested case-control study. <i>Annals of Medicine</i> , 2018, 50, 576-586.	3.8	61
71	Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism. <i>Cardiovascular Diabetology</i> , 2018, 17, 48.	6.8	33
72	Low-density lipoprotein-associated variables and the severity of coronary artery disease: an untreated Chinese cohort study. <i>Biomarkers</i> , 2018, 23, 647-653.	1.9	20

#	ARTICLE	IF	CITATIONS
73	The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia. <i>Atherosclerosis</i> , 2018, 277, 7-14.	0.8	22
74	Familial hypercholesterolemia in very young myocardial infarction. <i>Scientific Reports</i> , 2018, 8, 8861.	3.3	14
75	Association of invasive treatment and lower mortality of patients \geq 80 years with acute myocardial infarction: a propensity-matched analysis. <i>Journal of Geriatric Cardiology</i> , 2018, 15, 666-674.	0.2	3
76	ApoB is superior to LDL-C or non-HDL-C as a lipid marker for predicting the presence and severity of atherosclerosis in female patients with myocardial infarction. <i>Hellenic Journal of Cardiology</i> , 2017, 58, 223-225.	1.0	2
77	Plasma big endothelin-1 levels at admission and future cardiovascular outcomes: A cohort study in patients with stable coronary artery disease. <i>International Journal of Cardiology</i> , 2017, 230, 76-79.	1.7	29
78	Triglyceride to High-Density Lipoprotein Cholesterol Ratio and Cardiovascular Events in Diabetics With Coronary Artery Disease. <i>American Journal of the Medical Sciences</i> , 2017, 354, 117-124.	1.1	43
79	Distribution of ABO Blood Groups and Coronary Artery Calcium. <i>Heart Lung and Circulation</i> , 2017, 26, 593-598.	0.4	5
80	Serum fibrinogen and cardiovascular events in Chinese patients with type 2 diabetes and stable coronary artery disease: a prospective observational study. <i>BMJ Open</i> , 2017, 7, e015041.	1.9	28
81	High-density lipoprotein cholesterol levels are associated with coronary severity but not with outcomes in new-onset patients with stable coronary artery disease. <i>Atherosclerosis</i> , 2017, 263, 104-111.	0.8	7
82	Homozygous familial hypercholesterolemia in China: Case series from the national lipid clinics and literature review. <i>IJC Metabolic & Endocrine</i> , 2017, 14, 75-80.	0.5	1
83	Novel and traditional lipid-related biomarkers and their combinations in predicting coronary severity. <i>Scientific Reports</i> , 2017, 7, 360.	3.3	22
84	Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease. <i>Atherosclerosis</i> , 2017, 260, 67-74.	0.8	65
85	Familial Hypercholesterolemia Phenotype in Chinese Patients Undergoing Coronary Angiography. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 570-579.	2.4	49
86	Analysis of Lipoprotein Subfractions in 920 Patients With and Without Type 2 Diabetes. <i>Heart Lung and Circulation</i> , 2017, 26, 211-218.	0.4	12
87	Acute myocardial infarction caused by myocardial bridging alone confirmed by using intravascular ultrasonography. <i>Chronic Diseases and Translational Medicine</i> , 2017, 3, 260-262.	1.2	3
88	Elevated resting heart rate is associated with the severity of coronary artery disease in non-treated patients who underwent coronary angiography: potential role of lipoprotein subfractions. <i>Archives of Physiology and Biochemistry</i> , 2017, 123, 356-363.	2.1	7
89	Free fatty acids and cardiovascular outcome: a Chinese cohort study on stable coronary artery disease. <i>Nutrition and Metabolism</i> , 2017, 14, 41.	3.0	18
90	Big endothelin-1 level is a useful marker for predicting the presence of isolated coronary artery ectasia. <i>Biomarkers</i> , 2017, 22, 331-336.	1.9	7

#	ARTICLE	IF	CITATIONS
91	Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C. <i>Oncotarget</i> , 2017, 8, 12333-12341.	1.8	8
92	Association between fibrinogen level and the severity of coronary stenosis in 418 male patients with myocardial infarction younger than 35 years old. <i>Oncotarget</i> , 2017, 8, 81361-81368.	1.8	15
93	Positive correlation of plasma PCSK9 levels with HbA _{1c} in patients with type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 193-199.	4.0	36
94	Plasma PCSK9 level is unrelated to blood pressure and not associated independently with carotid intima-media thickness in hypertensives. <i>Hypertension Research</i> , 2016, 39, 598-605.	2.7	13
95	Is monocyte to HDL ratio superior to monocyte count in predicting the cardiovascular outcomes: evidence from a large cohort of Chinese patients undergoing coronary angiography. <i>Annals of Medicine</i> , 2016, 48, 305-312.	3.8	44
96	Plasma endothelin-1 level as a predictor for poor collaterals in patients with ≥95% coronary chronic occlusion. <i>Thrombosis Research</i> , 2016, 142, 21-25.	1.7	7
97	Clinical considerations of lipid target and goal in dyslipidemia control. <i>Chronic Diseases and Translational Medicine</i> , 2016, 2, 3-6.	1.2	1
98	Non-HDL-C is a Better Predictor for the Severity of Coronary Atherosclerosis Compared with LDL-C. <i>Heart Lung and Circulation</i> , 2016, 25, 975-981.	0.4	43
99	Enhanced proprotein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38 ^{MAPK} -HNF1 β pathway in HepG2 cells. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 2374-2383.	3.6	21
100	HDL subfractions and very early CAD: novel findings from untreated patients in a Chinese cohort. <i>Scientific Reports</i> , 2016, 6, 30741.	3.3	17
101	Identification of familial hypercholesterolemia in patients with myocardial infarction: A Chinese cohort study. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1344-1352.	1.5	32
102	Effect of glycemic and lipid achievements on clinical outcomes type 2 diabetic, Chinese patients with stable coronary artery disease. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 115-120.	2.3	7
103	C-reactive protein as a predictor for poor collateral circulation in patients with chronic stable coronary heart disease. <i>Annals of Medicine</i> , 2016, 48, 83-88.	3.8	10
104	Effects of Hedan Tablet (èç%#) on lipid profile, proprotein convertase subtilisin/kexin type 9 and high-density lipoprotein subfractions in patients with hyperlipidemia: A primary study. <i>Chinese Journal of Integrative Medicine</i> , 2016, 22, 660-665.	1.6	5
105	Free triiodothyronine in relation to coronary severity at different ages: Gensini score assessment in 4206 euthyroid patients. <i>Journal of Geriatric Cardiology</i> , 2016, 13, 978-983.	0.2	7
106	Lipid profiles in nontreated Chinese patients with stable coronary artery disease: a cross-sectional study. <i>Clinical Lipidology</i> , 2015, 10, 369-378.	0.4	1
107	Association of Big Endothelin-1 with Coronary Artery Calcification. <i>PLoS ONE</i> , 2015, 10, e0142458.	2.5	15
108	Systemic Inflammatory Markers Are Closely Associated with Atherogenic Lipoprotein Subfractions in Patients Undergoing Coronary Angiography. <i>Mediators of Inflammation</i> , 2015, 2015, 1-9.	3.0	9

#	ARTICLE	IF	CITATIONS
109	High-density lipoprotein subfractions in relation with the severity of coronary artery disease: A Gensini score assessment. <i>Journal of Clinical Lipidology</i> , 2015, 9, 26-34.	1.5	48
110	Relationship of High-Density Lipoprotein Cholesterol With Periprocedural Myocardial Injury Following Elective Percutaneous Coronary Intervention in Patients With Low-Density Lipoprotein Cholesterol Below 70 mg/dL. <i>Journal of the American Heart Association</i> , 2015, 4, e001412.	3.7	18
111	Update of Clinical Trials of Anti-PCSK9 Antibodies. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 159-169.	2.6	7
112	Circulating non-HDL-C levels were more relevant to atherogenic lipoprotein subfractions compared with LDL-C in patients with stable coronary artery disease. <i>Journal of Clinical Lipidology</i> , 2015, 9, 794-800.	1.5	18
113	Relationship of Glycated Hemoglobin Levels with Myocardial Injury following Elective Percutaneous Coronary Intervention in Patients with Type 2 Diabetes Mellitus. <i>PLoS ONE</i> , 2014, 9, e101719.	2.5	6
114	Association of Fibrinogen with Severity of Stable Coronary Artery Disease in Patients with Type 2 Diabetic Mellitus. <i>Disease Markers</i> , 2014, 2014, 1-8.	1.3	22
115	Policosanol Attenuates Statin-Induced Increases in Serum Proprotein Convertase Subtilisin/Kexin Type 9 When Combined with Atorvastatin. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-8.	1.2	12
116	PCSK9 gene mutations and low-density lipoprotein cholesterol. <i>Clinica Chimica Acta</i> , 2014, 431, 148-153.	1.1	37
117	Association of preprocedural low-density lipoprotein cholesterol levels with myocardial injury after elective percutaneous coronary intervention. <i>Journal of Clinical Lipidology</i> , 2014, 8, 423-432.	1.5	12
118	Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. <i>Atherosclerosis</i> , 2014, 234, 441-445.	0.8	96
119	Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis. <i>International Journal of Cardiology</i> , 2014, 174, 863-864.	1.7	39
120	Relation of Leukocytes and Its Subsets Counts with the Severity of Stable Coronary Artery Disease in Patients with Diabetic Mellitus. <i>PLoS ONE</i> , 2014, 9, e90663.	2.5	18
121	Evaluation of Red Blood Cell Distribution Width in Patients with Cardiac Syndrome X. <i>Disease Markers</i> , 2013, 34, 333-339.	1.3	9
122	Acute myocardial infarction in an 8-year old male child with homozygous familial hypercholesterolemia: laboratory findings and response to lipid-lowering drugs. <i>Clinical Laboratory</i> , 2013, 59, 901-7.	0.5	8